Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

Vetter's V-OVS® next Syringe Closure Wins Red Dot Design Concept Award
FDA Launches Initiative to Rethink Rare Disease Drug Development Framework
Senopsys Marks 20 Years of Sensory Science in Pharmaceutical Formulation Development
Biomapas Acquires Pinnaxis to Expand Drug Safety Technology Capabilities
Thermo Fisher Collaboration Identifies More Than 2,500 New Genetic-Protein Associations

  EXPERT CONTENT & RESOURCES

UPM

 

Monoclonal vs Polyclonal Antibody Production

Monoclonal vs Polyclonal Antibody Production

Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.

John Jansen

Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging

As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

The Future of Excipients in Drug Development: AI, Lipids & Next-Generation Formulation Strategies

The Future of Excipients in Drug Development: AI, Lipids & Next-Generation Formulation Strategies

  COMPANY PROFILE

Woodstock Sterile Solutions

Woodstock Sterile Solutions is a global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping healthcare companies advance molecules through clinical development into full-scale commercial production.

Throughout our 50-year history, Woodstock has been a leader in developing and deploying advanced aseptic blow-fill-seal delivery products.

We recently completed the expansion of our QC analytical laboratory, doubling the size of our previous space, and building on to our analytical expertise. We have enhanced our formulation and method development capabilities to offer fully integrated drug development and manufacturing services. We have continued to expand our blow-fill-seal capabilities. Working extensively with customers in the respiratory and ophthalmic markets for years, our BFS packaging offers viable solutions for healthcare companies in the diagnostics market as it helps to minimize the risk of human contamination, allows for precise filling and can be easily customized to meet specific needs for diagnostics customers.

Learn More

  WHITEPAPERS & WEBINARS

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 28 – Formulation Development
November 4 – Drug Delivery
November 11 – Parenteral Contract Manufacturing
November 18 – Controlled Release

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com